Liver Cancer
Conditions
Interventions
case series:Transarterial chemoembolization with epirubicin-loaded CalliSpheres microspheres
Sponsors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients aged between 18 to 80 years with hepatocellular carcinoma, with estimated survival time = 3 months; 2. BCLC stage B and BCLC stage A patients who are unsuitable or unwilling to undergo surgery or ablation; 3. Liver function Child-Pugh Class A or B; 4. ECOG performance status of 0 or 1; 5. patients and/or their legal representatives who agree to join the clinical trial and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Diffuse hepatocellular carcinoma; 2. Tumor burden =50% of total liver; 3. Vascular Invasion (main portal vein, primary branch of portal vein, trunk of three hepatic veins, inferior vena cava) or extrahepatic spread; 4. Severe liver function disorder (Child-Pugh grade C), including transaminase greater than 5 times the upper limit of normal, total bilirubin > 3.0 mg/dL, refractory ascites, hepatic encephalopathy or hepatorenal syndrome; 5. Uncorrectable coagulopathy; 6. White blood cell count 2 mg/dl or creatinine clearance < 30 ml/min); 9. Severe iodine contrast agent allergy; 10. Patients with dyscrasia or multiple organ failure; 11. Been received chemotherapy, ablation, transarterial embolization or chemoembolization.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression-free survival;serious adverse events; | — |
Countries
China
Contacts
Public ContactChuansheng Zheng
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Outcome results
None listed